230 related articles for article (PubMed ID: 33203517)
1. MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment.
Yarahmadi A; Shahrokhi SZ; Mostafavi-Pour Z; Azarpira N
Biochem Pharmacol; 2021 Jul; 189():114301. PubMed ID: 33203517
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA: A new generation therapeutic target in diabetic nephropathy.
Dewanjee S; Bhattacharjee N
Biochem Pharmacol; 2018 Sep; 155():32-47. PubMed ID: 29940170
[TBL] [Abstract][Full Text] [Related]
3. Circular RNAs; powerful microRNA sponges to overcome diabetic nephropathy.
Mafi A; Yadegar N; Salami M; Salami R; Vakili O; Aghadavod E
Pathol Res Pract; 2021 Nov; 227():153618. PubMed ID: 34649056
[TBL] [Abstract][Full Text] [Related]
4. TGF-Beta as a Master Regulator of Diabetic Nephropathy.
Wang L; Wang HL; Liu TT; Lan HY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360646
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy.
Kato M; Natarajan R
Semin Nephrol; 2012 May; 32(3):253-60. PubMed ID: 22835456
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the role of MicroRNAs in diabetic nephropathy: Regulatory mechanisms and molecular insights.
Abdelmaksoud NM; Al-Noshokaty TM; Abdelhamid R; Abdellatif N; Mansour A; Mohamed R; Mohamed AH; Khalil NAE; Abdelhamid SS; Mohsen A; Abdelaal H; Tawfik A; Elshaer SS
Pathol Res Pract; 2024 Apr; 256():155237. PubMed ID: 38492358
[TBL] [Abstract][Full Text] [Related]
7. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients.
Delić D; Eisele C; Schmid R; Baum P; Wiech F; Gerl M; Zimdahl H; Pullen SS; Urquhart R
PLoS One; 2016; 11(3):e0150154. PubMed ID: 26930277
[TBL] [Abstract][Full Text] [Related]
8. [The Role of TGF-β1/SMAD in Diabetic Nephropathy: Mechanisms and Research Development].
Wang Y; Guo J; Shao B; Chen H; Lan H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1065-1073. PubMed ID: 38162063
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
[TBL] [Abstract][Full Text] [Related]
10. The effects of expression of different microRNAs on insulin secretion and diabetic nephropathy progression.
Mafi A; Aghadavod E; Mirhosseini N; Mobini M; Asemi Z
J Cell Physiol; 2018 Jan; 234(1):42-50. PubMed ID: 30078212
[TBL] [Abstract][Full Text] [Related]
11. Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management.
Peng L; Chen Y; Shi S; Wen H
Stem Cell Res Ther; 2022 Jan; 13(1):25. PubMed ID: 35073973
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.
Kato M; Natarajan R
Ann N Y Acad Sci; 2015 Sep; 1353(1):72-88. PubMed ID: 25877817
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy, a targeted treatment for diabetic nephropathy.
Lin X; Tao L; Tang D
Curr Med Chem; 2013; 20(30):3774-84. PubMed ID: 23895680
[TBL] [Abstract][Full Text] [Related]
14. Captopril and Spironolactone Can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting microRNA-192 and microRNA-29a/b/c.
Ebadi Z; Moradi N; Kazemi Fard T; Balochnejadmojarrad T; Chamani E; Fadaei R; Fallah S
DNA Cell Biol; 2019 Oct; 38(10):1134-1142. PubMed ID: 31433203
[TBL] [Abstract][Full Text] [Related]
15. The Role of MicroRNA in the Pathogenesis of Diabetic Nephropathy.
Szostak J; Gorący A; Durys D; Dec P; Modrzejewski A; Pawlik A
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047185
[TBL] [Abstract][Full Text] [Related]
16. The role of microRNAs in diabetic nephropathy.
Wu H; Kong L; Zhou S; Cui W; Xu F; Luo M; Li X; Tan Y; Miao L
J Diabetes Res; 2014; 2014():920134. PubMed ID: 25258717
[TBL] [Abstract][Full Text] [Related]
17. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.
Rudnicki M; Beckers A; Neuwirt H; Vandesompele J
Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv35-42. PubMed ID: 26209736
[TBL] [Abstract][Full Text] [Related]
18. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7.
McClelland AD; Herman-Edelstein M; Komers R; Jha JC; Winbanks CE; Hagiwara S; Gregorevic P; Kantharidis P; Cooper ME
Clin Sci (Lond); 2015 Dec; 129(12):1237-49. PubMed ID: 26415649
[TBL] [Abstract][Full Text] [Related]
19. Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs.
Sankrityayan H; Kulkarni YA; Gaikwad AB
Pharmacol Res; 2019 Mar; 141():574-585. PubMed ID: 30695734
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by Targeting Transforming Growth Factor β (TGF-β)/smad Pathway and Pro-Inflammatory Cytokines.
Bai Y; Wang J; He Z; Yang M; Li L; Jiang H
Med Sci Monit; 2019 Apr; 25():3069-3076. PubMed ID: 31023998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
